Education
About Us
Working with TipRanks
Follow Us
Anteris Technologies Global Corp. (AVR)
:AVR
RESEARCH TOOLSreports
AVR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.34 - $8.79
Previous Close$5.88
Volume157.53K
Average Volume (3M)116.74K
Market Cap
$167.33M
Enterprise Value$110.67M
Total Cash (Recent Filing)$28.44M
Total Debt (Recent Filing)$2.81M
Price to Earnings (P/E)―
Beta1.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding36,062,370
10 Day Avg. Volume110,655
30 Day Avg. Volume116,741
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue44.64
Enterprise Value/Gross Profit75.14
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$12.83Price Target Upside176.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPreparations for the PARADIGM pivotal trial accelerated, with 79 sites qualified and global investigator meetings held.
Product PerformanceThe accumulating data reinforce the platform’s differentiated performance profile versus commercially available TAVR technologies.
Regulatory ProgressAnteris released its Q4 results, highlighting significant progress toward securing FDA approval for the DurAVR TAVR system.
Bears Say
Manufacturing ChallengesKey milestones include manufacturing scale-up, which is crucial for advancing the DurAVR toward pivotal trial.
Regulatory ChallengesThe company engaged in multiple pre-submission meetings with the FDA to review critical aspects of the pivotal trial.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $2.34 and its highest was $8.79 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $167.33M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on May 13, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.491 by -$0.119.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 36,062,370 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.491. Following the earnings report the stock price went up 6%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
Anteris Technologies Global Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.83 (176.51% Upside)
$12.83 (176.51% Upside)
Hedge Fund Trend
Decreased
By 434.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-615.48%
Trailing 12-Months
Asset Growth
137.36%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$12.83
▲(176.51% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
0.91% Mutual Funds
31.01% Other Institutional Investors
65.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---